Ascendis Pharma A/S vs Northrop Grumman Corporation — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Northrop Grumman Corporation trades at $575.54 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 4.9× Ascendis Pharma A/S's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NOC | |
|---|---|---|
Market Cap | $16.67B | $81.78B |
Sector | Health | Industrials |
52-Week High | $277.18 | $768.02 |
52-Week Low | $189.74 | $496.02 |
Enterprise Value | $17.04B | $95.77B |
Dividend Yield | — | 1.63% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →